01

Barzolvolimab Hits All Phase 3 End Points in Chronic Spontaneous Urticaria

Barzolvolimab, a KIT-targeting monoclonal antibody, met all primary and secondary end points in a Phase 3 chronic spontaneous urticaria trial, Dermatology Times reports.